Vyant Bio, Inc. announced that while the company cannot predict with certainty the amount of any possible liquidation payments, the company currently estimates that the liquidation payments to its shareholders will range from $0.16 to $0.29 per share, with the principal variable being the amount it receives with respect to the aggregate of $1.175 million of contingent payments provided for in the agreement for the sale of its assets.